Flurizan program worries hurt Myriad's stock

Myriad Genetics' stock continues to fall as investors fear poor results from a late-stage study of Flurizan for Alzheimer's. A phase II study of the drug found that Flurizan didn't benefit those with a moderate form of the disease, and Myriad designed the Phase III trial to focus on those with mild Alzheimer's. Investors aren't wild about the approach. "In a rush to Phase III, Myriad has made several critical mistakes, in our view," said one analyst.

- read the report for more

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.